http://www.medicalnewstoday.com/articles/84496.php
Promising Phase 3 Trial Results Show Novel Biologic Therapy
Ustekinumab (CNTO 1275) Significantly Improved Psoriasis
Article Date: 04 Oct 2007 - 0:00 PDT
The first reported findings from an international, Phase 3 study
showed that more than two-thirds of patients with moderate to severe
plaque psoriasis receiving two doses of ustekinumab (CNTO 1275)
achieved at least a 75 percent reduction in psoriasis at week 12, the
primary endpoint of the study, as measured by the Psoriasis Area and
Severity Index (PASI 75). Importantly, findings also showed that
following one additional dose at week 16, a substantial proportion of
patients receiving ustekinumab maintained a PASI 75 response through
week 28. Data from the study, presented at the World Congress of
Dermatology, involved more than 1,200 subjects and showed that within
four weeks of initiating treatment with ustekinumab, patients
experienced significant and clinically meaningful improvements in
quality of life measures compared with patients receiving placebo.
Ustekinumab is a new, fully-human monoclonal antibody with a novel
mechanism of action that targets the cytokines interleukin-12 (IL-12)
and interleukin-23 (IL-23), and is currently in Phase 3 development by
Centocor, Inc. for the treatment of moderate to severe plaque
psoriasis.
...
Interleukin-12 and Th1 immune response in Crohn's disease:
pathogenetic relevance and therapeutic implication.
http://www.ncbi.nlm.nih.gov/sites/entrez?db=pubmed&uid=17007011&cmd=s...
25 male,mainly proctitis,maybe Crohn's //
2x2 ASACOL (long term),2000 gm Asacol Suppositories,fish oil,vsl 3, folic acid ,2006 January flare up, 2006 MAY FLARE UP AGAIN (10 DAYS),june 2006
Peptic ulcers ,December 2006 esophagitis ,17/12/2006 azathioprine 100,14/01/
2007 Prednisone 20 for 2 weeks (mini flare)